Searched for
YOSHINDO
Biocon Biologics inks out-licensing agreement with Yoshindo IncUnder the terms of this deal, Japan-based Yoshindo gets exclusive commercialisation rights in Japan for Ustekinumab and Denosumab -- develo...- Lupin divests Kyowa Criticare to Neopharma GroupShares of Lupin closed at Rs 737, up marginally by 0.02 per cent, on Thursday.
- Lupin aims to be numero uno in biosimilar etanercept in JapanIt takes 12-13 months for the Japanese drug authorities to give product approvals.
- Lupin, Nichi-Iko tie up for commercialization of biosimilar Etanercept in JapanMumbai based Lupin pharma and Japan's Nichi-Iko have tied up for the distribution, promotion and sale of Lupin’s recently-filed biosimilar ...
- Lupin's JV completes global trials for RA biosimilarThe randomised trial of 52 weeks was conducted in 11 countries and included over 500 patients, Lupin said.
- Top stocks in focus on 09 February 2018Here is a list of top stocks that are likely to take focus in today's trading session.
- Top stocks in focus on 08 February 2018Take a look at top stocks that are likely to stay in limelight in today's trading.
- Indian generic drug makers like Lupin, Dr Reddy’s Laboratories, Sun Pharma eye Japanese marketIn April, Lupin formed a joint venture with Japan’s Yoshindo for biosimilars. It is also in talks with other local drug makers for alliance...
- Lupin to set up two new R&D centres in USLupin had also increased research and development spending to Rs 958.28 crore in FY'14 as compared to Rs 770.85 crore in the FY'13.
- Lupin forms Joint Venture with Japan's Yoshindo IncLupin's Etanercept biosimilar, developed by its Biotechnology Research Group in Pune will be the first product to be licensed for clinical ...
Load More
